journal
MENU ▼
Read by QxMD icon Read
search

Clinical Colorectal Cancer

journal
https://www.readbyqxmd.com/read/29398422/hormone-replacement-therapy-and-colorectal-cancer-incidence-and-mortality-in-the-prostate-lung-colorectal-and-ovarian-cancer-screening-trial
#1
Matthew M Symer, Natalie Z Wong, Jonathan S Abelson, Jeffrey W Milsom, Heather L Yeo
INTRODUCTION: Hormone replacement therapy has been shown to reduce colorectal cancer incidence, but its effect on colorectal cancer mortality is controversial. The objective of this study was to determine the effect of hormone replacement therapy on survival from colorectal cancer. PATIENTS AND METHODS: We performed a secondary analysis of data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a large multicenter randomized trial run from 1993 to 2001, with follow-up data recently becoming mature...
January 12, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29398423/frequency-of-surveillance-and-impact-of-surveillance-colonoscopies-in-patients-with-ulcerative-colitis-who-developed-colorectal-cancer
#2
Elisabeth B Cole, Yash Shah, Leon P McLean, Yu-Xiao Yang, Nabeel Khan
BACKGROUND: The risk of developing colorectal cancer (CRC) in patients with chronic ulcerative colitis (UC) is increased. The aim of this study was to evaluate if patients who developed CRC in the setting of UC were undergoing guideline-recommended surveillance colonoscopies and to determine the impact of surveillance on the staging of CRC. PATIENTS AND METHODS: Data was obtained from the Veterans Affairs healthcare system to identify patients with UC and CRC. Stage 0 and I were considered early-stage CRC, whereas stage ≥ II were considered advanced-stage CRC...
January 11, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29397328/cardiorespiratory-fitness-and-body-composition-responses-to-different-intensities-and-frequencies-of-exercise-training-in-colorectal-cancer-survivors
#3
James L Devin, David G Jenkins, Andrew T Sax, Gareth I Hughes, Joanne F Aitken, Suzanne K Chambers, Jeffrey C Dunn, Kate A Bolam, Tina L Skinner
INTRODUCTION: Deteriorations in cardiorespiratory fitness (V˙o2peak) and body composition are associated with poor prognosis after colorectal cancer treatment. However, the optimal intensity and frequency of aerobic exercise training to improve these outcomes in colorectal cancer survivors is unknown. PATIENTS AND METHODS: This trial compared 8 weeks of moderate-intensity continuous exercise (MICE; 50 minutes; 70% peak heart rate [HRpeak]; 24 sessions), with high-intensity interval exercise (HIIE; 4 × 4 minutes; 85%-95% HRpeak) at an equivalent (HIIE; 24 sessions) and tapered frequency (HIIE-T; 16 sessions) on V˙o2peak and on lean and fat mass, measured at baseline, 4, 8, and 12 weeks...
January 11, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29330005/a-phase-i-study-of-irinotecan-capecitabine-xeloda-and-oxaliplatin-in-patients-with-advanced-colorectal-cancer
#4
Jean Maroun, Horia Marginean, Derek Jonker, Christine Cripps, Rakesh Goel, Timothy Asmis, Rachel Goodwin, Gabriela Chiritescu
BACKGROUND: The objective of the present phase I study was to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of irinotecan, capecitabine, and oxaliplatin given in combination (IXO regimen) to patients with previously untreated, unresectable advanced or metastatic colorectal cancer (CRC). PATIENTS AND METHODS: Patients received oxaliplatin followed by irinotecan as intravenous infusions on day 1, with oral capecitabine taken twice daily (BID) on days 2 to 15 of a 3-week cycle...
December 15, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29311032/two-months-of-therapy-a-case-of-pathologic-complete-response-to-chemoimmunotherapy-in-a-patient-with-metastatic-colorectal-cancer
#5
Samantha Armstrong, Hayma Al-Ghawi, Paul Helft, Michael G House, Aaron J Spittler, Howard H Wu, Safi Shahda
No abstract text is available yet for this article.
December 13, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29305209/survival-benefit-of-palliative-local-treatments-and-efficacy-of-different-pharmacotherapies-in-colorectal-cancer-with-lung-metastasis-results-from-a-large-retrospective-study
#6
Zhenghang Wang, Xicheng Wang, Jiajia Yuan, Xiaotian Zhang, Jun Zhou, Ming Lu, Dan Liu, Jian Li, Lin Shen
BACKGROUND: For most colorectal cancer patients with initial lung metastasis (LM), the only suitable treatments are palliative, including palliative local therapy and pharmacotherapy. We investigated the role of palliative local treatments in prolonging survival and the efficacy of different pharmacotherapies. PATIENTS AND METHODS: After performing a medical record review of 2233 patients with metastatic colorectal cancer, 684 were identified as having LM. Their clinicopathologic characteristics, treatment patterns, and outcomes were analyzed retrospectively...
December 13, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29352642/lgals4-ceacam6-tspan8-and-col1a2-blood-markers-for-colorectal-cancer-validation-in-a-cohort-of-subjects-with-positive-fecal-immunochemical-test-result
#7
Maria Teresa Rodia, Rossella Solmi, Francesco Pasini, Elena Nardi, Gabriella Mattei, Giampaolo Ugolini, Luigi Ricciardiello, Pierluigi Strippoli, Rossella Miglio, Mattia Lauriola
BACKGROUND: A noninvasive blood test for the early detection of colorectal cancer (CRC) is highly required. We evaluated a panel of 4 mRNAs as putative markers of CRC. MATERIALS AND METHODS: We tested LGALS4, CEACAM6, TSPAN8, and COL1A2, referred to as the CELTiC panel, using quantitative reverse transcription polymerase chain reaction, on subjects with positive fecal immunochemical test (FIT) results and undergoing colonoscopy. Using a nonparametric test and multinomial logistic model, FIT-positive subjects were compared with CRC patients and healthy individuals...
December 12, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29306522/visceral-thromboses-in-pancreas-adenocarcinoma-systematic-review
#8
REVIEW
Angel Mier Hicks, Antonio DeRosa, Michael Raj, Richard Do, Kenneth H Yu, Maeve A Lowery, Anna Varghese, Eileen M O'Reilly
Within gastrointestinal malignancies, primary hepatocellular carcinoma and pancreatic ductal adenocarcinoma (PDAC) are frequently associated with visceral thromboses (VT). Thrombus formation in the portal (PVT), mesenteric (MVT), or splenic vein (SVT) system leads to portal hypertension and intestinal ischemia. VT in PDAC may convey a risk of increased distal thrombosis and poses therapeutic uncertainty regarding the role of anticoagulation. An increasing number of reports describe VT associated with PDAC. It is possible that early diagnosis of these events may help reduce morbidity and speculatively improve oncologic outcomes...
December 12, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29233603/individual-susceptibility-analysis-using-patient-derived-slice-cultures-of-colorectal-carcinoma
#9
Rasmus Sönnichsen, Laura Hennig, Vera Blaschke, Karsten Winter, Justus Körfer, Susann Hähnel, Astrid Monecke, Christian Wittekind, Boris Jansen-Winkeln, René Thieme, Ines Gockel, Kerstin Grosser, Arved Weimann, Christoph Kubick, Volker Wiechmann, Achim Aigner, Ingo Bechmann, Florian Lordick, Sonja Kallendrusch
BACKGROUND: Nonresponse to chemotherapy in colorectal carcinoma (CRC) is still a clinical problem. For most established treatment regimens, no predictive biomarkers are available. Patient-derived tumor slice culture may be a promising ex vivo technology to assess the drug susceptibility in individual tumors. METHODS: Patient-derived slice cultures of CRC specimens were prepared according to a standardized protocol and treated with different concentrations of 5-fluorouracil (5-FU) and an adapted FOLFOX regimen (5-FU and oxaliplatin) to investigate histologic response...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29223361/evidence-suggests-sphingosine-1-phosphate-might-be-actively-generated-degraded-and-transported-to-extracellular-spaces-with-increased-s1p2-and-s1p3-expression-in-colon%C3%A2-cancer
#10
Baasanjav Uranbileg, Takeshi Nishikawa, Hitoshi Ikeda, Makoto Kurano, Masaya Sato, Daisuke Saigusa, Junken Aoki, Toshiaki Watanabe, Yutaka Yatomi
BACKGROUND: A pivotal role of sphingosine 1-phosphate (S1P) in cancer has been suggested based on the ceramide-S1P rheostat theory that the intracellular balance between prosurvival S1P and proapoptotic ceramide determines cell fate. Upregulation of S1P-generating sphingosine kinases (SKs) and downregulation of S1P-degrading S1P lyase (SPL) might increase intracellular S1P levels to exert a prosurvival effect in cancer in general, such as colon cancer. However, we recently observed a distinct S1P metabolism in hepatocellular carcinoma tissues that increased SPL mRNA levels with reduced S1P levels...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29221688/primary-tumor-location-and-survival-in-the-general-population-with-metastatic-colorectal-cancer
#11
Shahid Ahmed, Punam Pahwa, Duc Le, Haji Chalchal, Selliah Chandra-Kanthan, Nayyer Iqbal, Anthony Fields
BACKGROUND: Recent evidence from clinical trials suggests that primary tumor location in patients with metastatic colorectal cancer correlates with differential outcomes, and patients with tumors originating in the right side of the colon have inferior survival. We conducted a large population-based cohort study using individual patient data to confirm the prognostic importance of primary tumor location in the general population with metastatic colorectal cancer. METHODS: A cohort of 1947 patients who were diagnosed with metastatic colorectal cancer from 1992 to 2010 was studied...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29221687/leptomeningeal-carcinomatosis-in-colorectal-cancer-the-mayo-clinic-experience
#12
Gretchen Taylor, Nina Karlin, Thorvardur R Halfdanarson, Kyle Coppola, Axel Grothey
BACKGROUND: Leptomeningeal metastasis (LM) is an uncommon form of metastatic disease in many cancers. There remains a paucity of literature with regard to the course and management of LM in colorectal cancers (CRCs). The aim of this study was to estimate the incidence of LM in patients with CRC seen at our institution over a 15-year period, and to describe the clinical course and outcome of these cases. METHODS: LM in CRC primary cases between 2000 and 2014 were identified in the Mayo Clinic databases...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29208445/optimal-interval-for-18f-fdg-pet-after-chemoradiotherapy-for-rectal-cancer
#13
Kazushige Kawai, Hiroaki Nozawa, Keisuke Hata, Toshiaki Tanaka, Takeshi Nishikawa, Koji Oba, Toshiaki Watanabe
INTRODUCTION: Although 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) has been increasingly used to evaluate the response to preoperative chemoradiotherapy (CRT) in patients with rectal cancer, the optimal intervals between completion of CRT, PET, and surgery have not been fully investigated. PATIENTS AND METHODS: A total of 148 consecutive patients with rectal adenocarcinoma who received CRT followed by FDG-PET and radical surgery were retrospectively analyzed...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29174481/a-comparison-of-regorafenib-and-tas-102-for-metastatic-colorectal-cancer-a-systematic-review-and-network-meta-analysis
#14
Ana B K Abrahao, Yoo-Joung Ko, Scott Berry, Kelvin K W Chan
BACKGROUND: Regorafenib and TAS-102 have shown to be superior to placebo in refractory metastatic colorectal cancer. However, no studies have directly compared both drugs. Giving the lack of standard options in this scenario, a systematic review to compare the efficacy and safety of regorafenib and TAS-102 was performed. MATERIALS AND METHODS: A systematic review using the PubMed, Medline, Embase, Scopus, and Cochrane databases to identify published and unpublished studies up to November 2015 for randomized controlled trials for patients with metastatic colorectal cancer, involving regorafenib or TAS-102, was performed...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28687458/effectiveness-of-screening-modalities-in-colorectal-cancer-a-network-meta-analysis
#15
REVIEW
Jianping Zhang, Zhiyuan Cheng, Yubao Ma, Caili He, Yongbin Lu, Yaxue Zhao, Xiaoyu Chang, Yawei Zhang, Yana Bai, Ning Cheng
The aim of the study was to evaluate on the effectiveness of screening modalities in the prevention of colorectal cancer (CRC) occurrence and deaths. General meta-analysis was performed to produce pooled estimates of the effect of CRC incidence and mortality using a search of PubMed, Web of Science, and the Cochrane Library for eligible studies from January 1992 to March 2016. A network meta-analysis was performed to synthetically compare the effectiveness of 5 frequently used screening modalities. A total of 44 studies with a focus on mortality from CRC using different screening methods were included...
December 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29157662/evaluation-of-guideline-adherence-in-colorectal-cancer-treatment-in-the-netherlands-a-survey-among-medical-oncologists-by-the-dutch-colorectal-cancer-group
#16
Lotte Keikes, Martijn G H van Oijen, Valery E P P Lemmens, Miriam Koopman, Cornelis J A Punt
BACKGROUND: Clinical guidelines are generated to preserve high-quality evidence-based care. Data on the implementation of guidelines into clinical practice are scarce, despite that guideline adherence prevents over- and undertreatment and correlates with survival. Therefore, we investigated guideline adherence for the systemic treatment in high-risk stage II and stage III colon cancer and metastatic colorectal cancer. PATIENTS AND METHODS: In all Dutch hospitals (n = 88) 1 medical oncologist involved in colorectal cancer care was approached to participate...
November 17, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29153429/optimal-interval-to-surgery-after-neoadjuvant-chemoradiotherapy-in-rectal-cancer-a%C3%A2-systematic-review-and-meta-analysis
#17
REVIEW
Donglin Du, Zhourong Su, Dan Wang, Wenwen Liu, Zhengqiang Wei
This study aimed to evaluate the influence of a waiting interval of ≥ 8 weeks between the end of preoperative neoadjuvant chemoradiotherapy (nCRT) and surgery on the outcomes of patients with locally advanced rectal cancer. We conducted a comprehensive literature review of retrospective and prospective studies from PubMed, Embase, and Cochrane Library databases to investigate the length of the preoperative nCRT-surgery waiting interval and outcomes in patients with locally advanced rectal cancer. The primary outcome measure was pathologic complete response (pCR) rate...
November 15, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29249584/planned-safety-analysis-of-the-acts-cc-02-trial-a-randomized-phase-iii-trial-of-s-1-with-oxaliplatin-versus-tegafur-and-uracil-with-leucovorin-as-adjuvant-chemotherapy-for-high-risk-stage-iii-colon-cancer
#18
Tetsuya Kusumoto, Eiji Sunami, Mitsuyoshi Ota, Kazuhiro Yoshida, Yoshiyuki Sakamoto, Naohiro Tomita, Atsuyuki Maeda, Izumi Mochizuki, Michio Okabe, Katsuyuki Kunieda, Junichiro Yamauchi, Michio Itabashi, Kenjiro Kotake, Keiichi Takahashi, Hideo Baba, Narikazu Boku, Keisuke Aiba, Megumi Ishiguro, Satoshi Morita, Kenichi Sugihara
BACKGROUND: This trial was designed to verify the superiority of 6 months of postoperative adjuvant chemotherapy with SOX (S-1 with oxaliplatin) with UFT (tegafur and uracil) with LV (leucovorin) in terms of disease-free survival in patients with high-risk stage III colon cancer. We report the results of a planned safety analysis. PATIENTS AND METHODS: Patients who underwent curative resection for high-risk stage III colon cancer (any T, N2, or positive nodes around the origin of the feeding arteries) were randomly assigned to receive either UFT/LV (300-600 mg/d UFT with 75 mg/d LV on days 1-28, every 35 days, for 5 cycles) or SOX (100 mg/m2 of oxaliplatin on day 1 with 80-120 mg/d S-1 on days 1-14, every 21 days, for 8 cycles)...
November 1, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29195807/parallel-evaluation-of-circulating-tumor-dna-and-circulating-tumor-cells-in-metastatic-colorectal-cancer
#19
Giovanni Germano, Gianluca Mauri, Giulia Siravegna, Caroline Dive, Jackie Pierce, Federica Di Nicolantonio, Maurizio D'Incalci, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi
BACKGROUND: Tissue biopsy is the gold standard for tumor genotyping, but it is an invasive procedure providing a single snapshot into tumor heterogeneity. Liquid biopsy approaches, encompassing the analysis of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), have been proposed as an alternative, with the potential of providing a comprehensive portrait of the tumor molecular landscape. In metastatic colorectal cancer (mCRC), both CTCs and ctDNA analysis have been investigated, but comparative analyses are limited...
November 1, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29223362/autophagy-inhibition-in-pancreatic-adenocarcinoma
#20
REVIEW
Brian A Boone, Herbert J Zeh, Nathan Bahary
Although some progress has been made in recent years with the development of more effective chemotherapy regimens, new treatment approaches are needed to improve outcomes for patients with pancreatic adenocarcinoma. The cellular process of autophagy, a cell survival mechanism that allows cancer cells to survive the hazardous conditions of the tumor microenvironment and treatment, has emerged as a viable target in pancreatic cancer. We review the mechanism of autophagy, its role in pancreatic carcinogenesis, the preclinical and clinical evidence supporting targeting autophagy in patients with pancreatic adenocarcinoma, and areas of future investigation that hold promise for improving this treatment approach...
October 28, 2017: Clinical Colorectal Cancer
journal
journal
39741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"